RxDoctor Payments Data

Benjamin Hocutt

Acute Care · Greenville, NCNPI 1063817773

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $19,300 of the $25,344 with a category attached, or 76.2%. 17 manufacturers reported payments, led by Scpharmaceuticals Inc. at 46.6% of the total. Among acute care clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,344in general payments, 2019–2025

Across 89 payments — averaging $284.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scpharmaceuticals Inc.$12K
  • Lexicon Pharmaceuticals, Inc.$9K
  • Merck$2K
  • Novartis$919
  • Abbott$831
  • Abiomed$486
  • plus $723 from 11 others

What the payments were for

  • Consulting fees$8123%
  • Speaking & faculty fees$19,30076%
  • Travel & lodging$1,1174%
  • Food & beverage$4,11516%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,344 in reported general payments places this provider in the 95th percentile of 312 acute care providers in North Carolina.

See all acute care providers in North Carolina

Medicare billing

Part B allowed, 2024
$5,301
Medicare patients
39
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan28$18,896
FarxigaDapagliflozin Propanediol24$17,275
JardianceEmpagliflozin11$8,701
Spironolactone34$266
Torsemide21$192
Metoprolol Succinate20$190
Carvedilol13$58
Losartan Potassium15$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$919$18,89628 claims
AstraZenecaFarxiga$165$17,27524 claims
Boehringer IngelheimJardiance$81$8,70111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 acute care providers in North Carolina.

Other acute care in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →